Trial Profile
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemigliptin/rosuvastatin (Primary) ; Gemigliptin; Rosuvastatin
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BALANCE
- Sponsors LG Life Sciences
- 08 Dec 2017 Results assessing efficacy and safety of Fixed dose combination of gemigliptin and rosuvastatin, presented at the 2017 Congress of the International Diabetes Federation.
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Primary endpoint has been met. (LDL-C change rate) as per results presented at the 77th Annual Scientific Sessions of the American Diabetes Association